Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM.

Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9.

PMID:
31515154
2.

Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.

Govek SP, Bonnefous C, Julien JD, Nagasawa JY, Kahraman M, Lai AG, Douglas KL, Aparicio AM, Darimont BD, Grillot KL, Joseph JD, Kaufman JA, Lee KJ, Lu N, Moon MJ, Prudente RY, Sensintaffar J, Rix PJ, Hager JH, Smith ND.

Bioorg Med Chem Lett. 2019 Feb 1;29(3):367-372. doi: 10.1016/j.bmcl.2018.12.042. Epub 2018 Dec 19.

PMID:
30587451
3.

A biosensor-based approach reveals links between efflux pump expression and cell cycle regulation in pleiotropic drug resistance of yeast.

Li J, Kolberg K, Schlecht U, St Onge RP, Aparicio AM, Horecka J, Davis RW, Hillenmeyer ME, Harvey CJB.

J Biol Chem. 2019 Jan 25;294(4):1257-1266. doi: 10.1074/jbc.RA118.003904. Epub 2018 Dec 4.

PMID:
30514758
4.

Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research.

Meeks JJ, Goldkorn A, Aparicio AM, McConkey DJ.

Urol Oncol. 2019 May;37(5):313-317. doi: 10.1016/j.urolonc.2018.06.008. Epub 2018 Aug 13. Review.

5.

Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.

Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF.

Eur Urol. 2018 Aug;74(2):140-143. doi: 10.1016/j.eururo.2018.03.031. Epub 2018 Apr 12.

PMID:
29656854
6.

Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers.

Soundararajan R, Aparicio AM, Logothetis CJ, Mani SA, Maity SN.

Front Oncol. 2018 Mar 15;8:69. doi: 10.3389/fonc.2018.00069. eCollection 2018. Review.

7.

Reply to Comment on "Alternative acute oral toxicity assessment under REACH based on sub-acute toxicity values".

Gissi A, Louekari K, Hoffstadt L, Bornatowicz N, Aparicio AM.

ALTEX. 2018;35(1):121-122. doi: 10.14573/altex.1712011. No abstract available.

8.

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC.

Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.

9.

Quantitative analysis of protein interaction network dynamics in yeast.

Celaj A, Schlecht U, Smith JD, Xu W, Suresh S, Miranda M, Aparicio AM, Proctor M, Davis RW, Roth FP, St Onge RP.

Mol Syst Biol. 2017 Jul 13;13(7):934. doi: 10.15252/msb.20177532.

10.

Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience With 101 Patients.

Ganeshan D, Aparicio AM, Morani A, Kundra V.

AJR Am J Roentgenol. 2017 Aug;209(2):327-332. doi: 10.2214/AJR.16.17214. Epub 2017 Jun 7.

PMID:
28590819
11.

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.

Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.

Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

12.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

13.

Role of radical prostatectomy in metastatic prostate cancer: A review.

Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF.

Urol Oncol. 2017 Apr;35(4):125-134. doi: 10.1016/j.urolonc.2017.01.001. Epub 2017 Feb 9. Review.

PMID:
28190749
14.

Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC.

Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948. Review.

15.

Alternative acute oral toxicity assessment under REACH based on sub-acute toxicity values.

Gissi A, Louekari K, Hoffstadt L, Bornatowicz N, Aparicio AM.

ALTEX. 2017;34(3):353-361. doi: 10.14573/altex.1609121. Epub 2016 Nov 8.

16.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12786-12791. doi: 10.1073/pnas.1615400113. Epub 2016 Oct 24.

17.

Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?

Logothetis CJ, Aparicio AM.

J Clin Oncol. 2016 Aug 20;34(24):2810-1. doi: 10.1200/JCO.2016.68.4738. Epub 2016 Jul 18. No abstract available.

PMID:
27432923
18.

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.

Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ.

Clin Cancer Res. 2016 Mar 15;22(6):1520-30. doi: 10.1158/1078-0432.CCR-15-1259. Epub 2015 Nov 6.

19.

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Govek SP, Nagasawa JY, Douglas KL, Lai AG, Kahraman M, Bonnefous C, Aparicio AM, Darimont BD, Grillot KL, Joseph JD, Kaufman JA, Lee KJ, Lu N, Moon MJ, Prudente RY, Sensintaffar J, Rix PJ, Hager JH, Smith ND.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5163-7. doi: 10.1016/j.bmcl.2015.09.074. Epub 2015 Oct 3.

PMID:
26463130
20.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC.

Sci Signal. 2014 May 20;7(326):ra47. doi: 10.1126/scisignal.2005070.

21.

Mapping the cellular response to small molecules using chemogenomic fitness signatures.

Lee AY, St Onge RP, Proctor MJ, Wallace IM, Nile AH, Spagnuolo PA, Jitkova Y, Gronda M, Wu Y, Kim MK, Cheung-Ong K, Torres NP, Spear ED, Han MK, Schlecht U, Suresh S, Duby G, Heisler LE, Surendra A, Fung E, Urbanus ML, Gebbia M, Lissina E, Miranda M, Chiang JH, Aparicio AM, Zeghouf M, Davis RW, Cherfils J, Boutry M, Kaiser CA, Cummins CL, Trimble WS, Brown GW, Schimmer AD, Bankaitis VA, Nislow C, Bader GD, Giaever G.

Science. 2014 Apr 11;344(6180):208-11. doi: 10.1126/science.1250217. Erratum in: Science. 2014 May 23;344(6186):1255771.

22.

A functional screen for copper homeostasis genes identifies a pharmacologically tractable cellular system.

Schlecht U, Suresh S, Xu W, Aparicio AM, Chu A, Proctor MJ, Davis RW, Scharfe C, St Onge RP.

BMC Genomics. 2014 Apr 5;15:263. doi: 10.1186/1471-2164-15-263.

23.

Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.

Goldkorn A, Aparicio AM, Quinn DI.

Ann Oncol. 2013 Jul;24(7):1717-20. doi: 10.1093/annonc/mdt234. No abstract available.

PMID:
23798673
24.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ.

Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.

25.

Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK.

PLoS One. 2012;7(11):e48787. doi: 10.1371/journal.pone.0048787. Epub 2012 Nov 30.

26.

Molecular probe technology detects bacteria without culture.

Hyman RW, St Onge RP, Kim H, Tamaresis JS, Miranda M, Aparicio AM, Fukushima M, Pourmand N, Giudice LC, Davis RW.

BMC Microbiol. 2012 Mar 9;12:29. doi: 10.1186/1471-2180-12-29.

27.

Epigenetics in prostate cancer.

Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM.

Prostate Cancer. 2011;2011:580318. doi: 10.1155/2011/580318. Epub 2011 Nov 30.

28.

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM.

Clin Cancer Res. 2012 Feb 1;18(3):666-77. doi: 10.1158/1078-0432.CCR-11-1867. Epub 2011 Dec 12.

29.

Hypomethylating agents for urologic cancers.

Alva AS, Hahn NM, Aparicio AM, Singal R, Yellapragada S, Sonpavde G.

Future Oncol. 2011 Mar;7(3):447-63. doi: 10.2217/fon.11.9. Review.

PMID:
21417907
30.

Multiplex identification of microbes.

Hyman RW, St Onge RP, Allen EA, Miranda M, Aparicio AM, Fukushima M, Davis RW.

Appl Environ Microbiol. 2010 Jun;76(12):3904-10. doi: 10.1128/AEM.02785-09. Epub 2010 Apr 23.

31.

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD.

Urol Oncol. 2011 Nov-Dec;29(6):682-9. doi: 10.1016/j.urolonc.2009.09.015. Epub 2009 Dec 3.

PMID:
19959380
32.

Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.

Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ.

BMC Med Genomics. 2009 Aug 4;2:48. doi: 10.1186/1755-8794-2-48.

33.

Effects of two chelating agents (EDTA and DTPA) on the autochthonous vegetation of a soil polluted with Cu, Zn and Cd.

Pastor J, Aparicio AM, Gutierrez-Maroto A, Hernández AJ.

Sci Total Environ. 2007 May 25;378(1-2):114-8. Epub 2007 Feb 20.

PMID:
17307245
34.

Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.

Egger G, Aparicio AM, Escobar SG, Jones PA.

Cancer Res. 2007 Jan 1;67(1):346-53.

35.

The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.

Aparicio AM, Elkhouiery AB, Quinn DI.

Urol Clin North Am. 2005 May;32(2):217-30, vii. Review.

PMID:
15862619
36.

Spiral aftereffect test and rapid picture projection test with aging populations.

Kaye J, Boyle E Jr, Canosa FL, Aparicio AM, Morgan HW.

J Am Geriatr Soc. 1976 Sep;24(9):394-401. No abstract available.

PMID:
956585
37.

Auditory and visual memory losses in aging populations.

Boyle E Jr, Aparicio AM, Kaye J, Acker M.

J Am Geriatr Soc. 1975 Jun;23(6):284-6.

PMID:
1127202

Supplemental Content

Loading ...
Support Center